Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott, Charles G. Drake, Mario Sznol et al. · Journal of Clinical Oncology · 2015
PURPOSE: Blockade of the programmed death-1 inhibitory cell-surface molecule on immune cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor regression in a portion of patients with advanced treatment-refractory solid tumors. We report clinical activity, survival, and long-term safety in patients with advanced renal cell carcinoma (RCC) treated with nivolumab in a phase I study with expansion cohorts. PATIENTS AND METHODS: A total of 34 patients with previously treated advanced RCC, enrolled between 2008 and 2012, received intravenous nivolumab (1 or 10 mg/kg) in an outpatient setting once every two weeks for up to 96 weeks and were observed for survival and duration of response after treatment discontinuation. RESULTS: Ten patients (29%) achieved objective responses (according to RECIST [version 1.0]), with median response duration of 12.9 months; nine additional patients (27%) demonstrated stable disease lasting > 24 weeks. Three of five patients who stopped treatment while in response continued to respond for ≥ 45 weeks. Median overall survival in all patients (71% with two to five prior systemic therapies) was 22.4 months; 1-, 2-, and 3-year survival rates were 71%, 48%, and 44%, respectively. Grade 3 to 4 treatment-related adverse events occurred in 18% of patients; all were reversible. CONCLUSION: Patients with advanced treatment-refractory RCC treated with nivolumab demonstrated durable responses that in some responders persisted after drug discontinuation. Overall survival is encouraging, and toxicities were generally manageable. Ongoing randomized clinical trials will further assess the impact of nivolumab on overall survival in patients with advanced RCC.
Cited by 439 works. doi:10.1200/jco.2014.58.1041
Authors
- David F. McDermott
- Charles G. Drake
- Mario Sznol
- Toni K. Choueiri
- John D. Powderly
- David Carl Smith
- Julie Renee Brahmer
- Richard D. Carvajal
- Hans J. Hammers
- Igor J. Puzanov
- Frank Stephen Hodi
- Harriet M. Kluger
- Suzanne Louise Topalian
- Drew M. Pardoll
- Jon M. Wigginton
- Georgia D. Kollia
- Ashok Kumar Gupta
- Dan McDonald
- Vindira Sankar
- Jeffrey Alan Sosman
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria